Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe?

[1]  A. de Gottardi,et al.  EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. , 2022, Journal of hepatology.

[2]  H. Yoshiji,et al.  Baveno VII - Renewing consensus in portal hypertension. , 2021, Journal of hepatology.

[3]  N. Syn,et al.  Meta‐analysis and systematic review: Prevalence, graft failure, mortality, and post‐operative thrombosis in liver transplant recipients with pre‐operative portal vein thrombosis , 2021, Clinical transplantation.

[4]  Rongsheng Zhao,et al.  A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat? , 2021, Hepatology International.

[5]  G. Su,et al.  AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. , 2021, Gastroenterology.

[6]  N. Syn,et al.  A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis , 2021, Hepatology International.

[7]  A. de Gottardi,et al.  Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. , 2021, Digestive and Liver Disease.

[8]  M. Trauner,et al.  Safety of direct oral anticoagulants in patients with advanced liver disease , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[9]  N. Syn,et al.  Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation and Concomitant Liver Cirrhosis: A Systematic Review and Meta-Analysis , 2021, American Journal of Cardiovascular Drugs.

[10]  D. Valla,et al.  Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases , 2020, Hepatology.

[11]  V. De Stefano,et al.  Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis , 2020, Advances in Therapy.

[12]  T. Schiano,et al.  Safety, Efficacy, and Long-Term Outcomes of Anticoagulation in Cirrhotic Portal Vein Thrombosis , 2020, Digestive Diseases and Sciences.

[13]  P. Thuluvath,et al.  Systematic review with meta‐analysis: abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis , 2020, Alimentary pharmacology & therapeutics.

[14]  W. Ageno,et al.  Anticoagulant therapy for splanchnic vein thrombosis: A systematic review and meta-analysis. , 2020, Blood.

[15]  Yueyue Li,et al.  Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial , 2020, Clinical and translational gastroenterology.

[16]  P. Northup,et al.  Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients with Decompensated Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  C. Elayi,et al.  Mortality and morbidity in patients with atrial fibrillation and liver cirrhosis , 2020, World journal of cardiology.

[18]  P. Reese,et al.  Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation , 2020, Hepatology.

[19]  Bao-yan Xu,et al.  Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients with Cirrhosis and Acute Decompensation. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  Douglas A. Simonetto,et al.  ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. , 2020, The American journal of gastroenterology.

[21]  Yingyi Qin,et al.  Atrial fibrillation in hospitalized patients with end‐stage liver disease: temporal trends in prevalence and outcomes , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[22]  Seil Oh,et al.  Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. , 2019, Journal of the American College of Cardiology.

[23]  K. Reddy,et al.  Impact of Chronic Kidney Disease on Outcomes in Cirrhosis , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  C. Thongprayoon,et al.  Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  F. Ramalho,et al.  Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis , 2019, Digestive Diseases and Sciences.

[26]  Mohammed M. Dawoud,et al.  Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. , 2019, Vascular pharmacology.

[27]  C. Crawford,et al.  Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort , 2018, Journal of gastroenterology and hepatology.

[28]  F. Carrilho,et al.  Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. , 2019, Journal of hepatology.

[29]  Z. Sparchez,et al.  Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis , 2018, The American Journal of Gastroenterology.

[30]  E. Liguori,et al.  Coagulation, Microenvironment and Liver Fibrosis , 2018, Cells.

[31]  A. Lebreton,et al.  Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis , 2018, Journal of thrombosis and haemostasis : JTH.

[32]  R. Goldin,et al.  Thrombin and factor Xa link the coagulation system with liver fibrosis , 2018, BMC Gastroenterology.

[33]  Keith T. Veltri,et al.  Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation , 2018, European journal of haematology.

[34]  D. Bauer,et al.  Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity , 2018, Alimentary pharmacology & therapeutics.

[35]  S. Caldwell,et al.  Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis , 2018, Clinical and Translational Gastroenterology.

[36]  A. Farcomeni,et al.  Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. , 2017, Gastroenterology.

[37]  M. Avila,et al.  The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells , 2017, Hepatology.

[38]  A. de Gottardi,et al.  Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[39]  E. Black-Maier,et al.  Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? , 2017, Heart.

[40]  D. Christodoulou,et al.  von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. , 2016, Journal of hepatology.

[41]  J. Bosch,et al.  Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. , 2016, Journal of hepatology.

[42]  X. Qi,et al.  Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature. , 2015, Clinics and research in hepatology and gastroenterology.

[43]  G. Stukenborg,et al.  Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. , 2015, World journal of hepatology.

[44]  A. Blasi.  Coagulopathy in liver disease: Lack of an assessment tool. , 2015, World journal of gastroenterology.

[45]  E. Horváth-Puhó,et al.  Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism , 2015, Clinical and Translational Gastroenterology.

[46]  G. Ioannou,et al.  Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  J. Uhm,et al.  The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. , 2015, International journal of cardiology.

[48]  R. Ehman,et al.  Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces , 2015, Hepatology.

[49]  S. Caldwell,et al.  Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[50]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[51]  C. Cuervo,et al.  Efficacy and safety of the use of heparin as thromboprophylaxis in patients with liver cirrhosis: a systematic review and meta-analysis. , 2013 .

[52]  P. Mannucci,et al.  Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. , 2013, Journal of hepatology.

[53]  Samuel S. Lee,et al.  Portal Vein Thrombosis: Should Anticoagulation Be Used? , 2013, Current Gastroenterology Reports.

[54]  D. Valla,et al.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.

[55]  H. Janssen,et al.  Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests , 2012, Journal of thrombosis and haemostasis : JTH.

[56]  A. Burroughs,et al.  Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? , 2011, Journal of hepatology.

[57]  G. Nguyen,et al.  Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[58]  R. Porte,et al.  Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. , 2010, Blood.

[59]  F. Violi,et al.  Hyperfibrinolysis in liver disease. , 2009, Clinics in liver disease.

[60]  E. Horváth-Puhó,et al.  Risk of Venous Thromboembolism in Patients With Liver Disease: A Nationwide Population-Based Case–Control Study , 2009, The American Journal of Gastroenterology.

[61]  P. Mannucci,et al.  Thrombin generation in patients with cirrhosis: The role of platelets , 2006, Hepatology.